EU Clinical Trials Regulation: Updated Requirements for CTIS Submissions
Published December 2025 — Detailed analysis of the European Medicines Agency's updated technical specifications for the Clinical Trials Information System, covering protocol amendments, safety reporting, annual reporting, and multi-country trial coordination.
The EU Clinical Trials Regulation
The EU Clinical Trials Regulation (CTR), Regulation (EU) No 536/2014, replaced the Clinical Trials Directive (2001/20/EC) as the governing framework for clinical trials conducted in the European Union. The CTR became fully applicable on January 31, 2022, alongside the launch of the Clinical Trials Information System (CTIS) — a centralized portal through which all clinical trial applications, amendments, safety reports, and annual reports for EU trials must be submitted.
The transition from the Directive to the Regulation was motivated by several critical objectives: harmonizing clinical trial authorization across EU member states, reducing administrative burden for multi-country trials, increasing transparency through public access to trial information, and establishing a single submission and assessment pathway for all clinical trial activities in the EU.
Since its launch, CTIS has undergone multiple functional updates as the EMA and member state competent authorities have refined the system based on operational experience and stakeholder feedback. The December 2025 update represents the most significant set of technical specification changes since the initial rollout, addressing known pain points in protocol amendment submissions, safety reporting workflows, and annual reporting requirements.
Updated Requirements
The December 2025 CTIS update introduces changes across four key functional areas. Sponsors conducting EU trials should review their submission workflows and internal timelines to accommodate these updates.
The updated specifications introduce a revised categorization system for substantial modifications, distinguishing between Category A amendments (safety-related changes requiring expedited review), Category B amendments (efficacy-related protocol modifications), and Category C amendments (administrative or logistical changes). Each category follows a distinct review timeline and documentation pathway within CTIS.
Safety reporting workflows have been restructured to align with the EudraVigilance integration roadmap. Sponsors must now submit Suspected Unexpected Serious Adverse Reaction (SUSAR) reports through a unified CTIS-EudraVigilance interface, eliminating the need for parallel submissions. Development Safety Update Reports (DSURs) must also be submitted through CTIS with enhanced structured data fields.
The annual safety report requirements have been expanded to include structured summaries of enrollment demographics, protocol deviation trending, and data quality metrics — in addition to the existing safety data requirements. These additions align with the EU's broader transparency objectives and will be partially accessible to the public through the CTIS transparency portal.
For trials conducted across multiple EU member states, the update introduces enhanced coordination mechanisms between the Reporting Member State (RMS) and Member States Concerned (MSCs). New shared assessment timelines and structured communication templates aim to reduce divergent national-level queries and streamline the consolidated assessment process.
Technical Specifications
The updated technical specifications address several operational challenges that sponsors and regulatory affairs teams have encountered since the CTIS launch. Understanding these changes is essential for maintaining compliant and efficient submission workflows.
Document Formatting Requirements
CTIS now enforces stricter document formatting standards for all uploaded files. PDF documents must comply with PDF/A-1a or PDF/A-2a format to ensure long-term archival accessibility. The maximum file size per document has been increased from 100 MB to 250 MB, but sponsors are encouraged to optimize file sizes where possible to facilitate reviewer access. All documents must include structured bookmarks corresponding to their table of contents, and cover pages must include the EU CT number, sponsor name, and document version date.
A new document naming convention has been introduced that incorporates the EU CT number, document type code, and version number in a standardized format. Documents that do not conform to the naming convention will trigger a validation warning in CTIS, potentially delaying the submission review clock.
Submission Timelines
The update revises several key submission timelines. For initial applications, the Part I assessment timeline remains 45 days with a possible clock stop, but a new 10-day administrative completeness check has been formalized — meaning sponsors should plan for up to 55 days for Part I assessment. Part II assessment by individual member states remains 45 days. For substantial modifications, Category A amendments must be reviewed within 20 days, Category B within 35 days, and Category C within 14 days.
Importantly, the update introduces a “fast-track modification” pathway for urgent safety-related amendments. Under this pathway, the RMS can authorize implementation of safety measures prior to completion of the full assessment, provided the sponsor submits a complete substantial modification application within 15 days of implementing the urgent measure.
Portal Functionality Updates
Several long-requested portal functionality improvements are included in the update. A new dashboard view provides sponsors with a consolidated overview of all active trials, pending submissions, and outstanding queries across member states. The messaging system has been enhanced to support structured query categories, making it easier for sponsors to route incoming queries to the appropriate internal teams. Bulk upload functionality has been added for multi-document submissions, and an API interface is now available for sponsors who wish to integrate CTIS submissions with their internal regulatory information management systems.
Impact on Multi-Country Trials
The updated requirements have particular significance for sponsors conducting clinical trials across multiple EU member states — which represents the majority of pivotal trials in the EU.
The revised multi-country coordination mechanisms are designed to reduce the frequency and severity of divergent national assessments. Under the previous workflow, individual member states could raise substantially different questions about the same protocol, creating administrative burden and timeline uncertainty. The new structured assessment templates and enhanced RMS-MSC communication protocols aim to identify and resolve potential divergences earlier in the review process, reducing the number of country-specific requests for information.
Despite the harmonization objectives, certain aspects of clinical trial authorization remain subject to national requirements. Part II assessment — covering ethics committee review, informed consent documentation, investigator suitability, site adequacy, and national insurance/indemnity requirements — continues to be conducted at the member state level. Sponsors must continue to prepare country-specific documentation for Part II requirements, including translated informed consent forms, local investigator CVs, and national insurance certificates.
The update clarifies and expands the responsibilities of the Reporting Member State (RMS) in multi-country trials. The RMS now serves as the primary coordination point for all Part I assessment activities, including facilitation of joint assessments, management of shared timelines, and resolution of inter-state queries. Sponsors should establish strong working relationships with the RMS early in the trial planning process, as the choice of RMS can significantly influence the efficiency of the overall assessment process.
Transition Considerations
Sponsors with ongoing trials face specific transition considerations depending on whether their studies were originally authorized under the Clinical Trials Directive or the Clinical Trials Regulation.
Studies initially authorized under the Directive that have not yet transitioned to the Regulation must complete their transition by December 31, 2027 — the final deadline established by the CTR. After this date, all clinical trials in the EU must be managed exclusively through CTIS. Sponsors who have not yet initiated the transition process for Directive-authorized trials should begin immediately, as the transition requires a complete regulatory submission through CTIS that must be assessed by all relevant member states.
Studies already authorized under the Regulation and managed through CTIS will automatically be subject to the updated technical specifications. Sponsors should review their existing CTIS submission templates and workflows to ensure compliance with the new formatting, naming, and timeline requirements. Any submissions in progress at the time of the update should be reviewed against the new specifications before finalization.
The conversion process for Directive-authorized trials is not merely administrative. It requires sponsors to compile a complete CTIS application dossier including all current protocol documents, investigator information, site details, and accumulated safety data in the format required by the Regulation. Sponsors should allocate adequate regulatory affairs resources and budget for this process, particularly for trials with complex amendment histories.
Practical Guidance: CTIS Submission Process
Based on our experience supporting sponsors through the CTIS submission process, the following step-by-step guidance addresses the updated requirements and highlights common pitfalls to avoid.
Pre-Submission Planning
Begin CTIS preparation at least 12 weeks before the intended submission date. This timeline accounts for document preparation, internal review, CTIS account setup (if needed), and a pre-submission meeting with the RMS if applicable. Identify all member states where the trial will be conducted and confirm whether the trial qualifies for the simplified assessment procedure (for low-intervention clinical trials) or requires the standard assessment pathway.
Document Preparation
Prepare all Part I and Part II documents in accordance with the updated formatting and naming conventions. Use the CTIS document templates published by the EMA's CTIS training program as a starting point. Ensure all PDF documents are in PDF/A format, include structured bookmarks, and comply with the naming convention. Prepare country-specific Part II documents for each member state, including translated consent forms and local regulatory requirements.
Dossier Assembly in CTIS
Upload all documents to CTIS using the structured dossier format. Verify that all mandatory fields are completed and that cross-references between documents are accurate. Use the CTIS validation tool to check for formatting errors, missing fields, and naming convention violations before submitting. Address all validation warnings — even those classified as non-blocking — as they may cause delays during the administrative completeness check.
Submission and Tracking
Submit the application through CTIS and document the submission date and EU CT number. Monitor the CTIS dashboard for communications from the RMS and MSCs. Set up internal alerts for assessment timeline milestones, including the Day 10 administrative completeness check, the Day 26 preliminary assessment for multi-country trials, and any clock-stop notifications. Assign dedicated personnel to monitor CTIS communications daily during the assessment period.
Query Management
Respond to RMS and MSC queries within the specified response timelines. Use the structured query response format introduced in the update. When queries require protocol clarification, coordinate the response across all relevant internal teams (clinical, regulatory, medical writing) before submitting. Track all queries and responses in your regulatory information management system for audit trail purposes.
Post-Authorization Compliance
After authorization, ensure all post-authorization obligations are tracked in CTIS, including substantial modification timelines, safety reporting schedules, and annual report deadlines. Set up automated reminders for recurring obligations. Maintain the CTIS dossier as a living record — ensuring that all amendments, safety updates, and enrollment milestones are reflected in the system in real time.
Common Pitfalls to Avoid
Based on the first three years of CTIS operations, the following issues have been the most frequent causes of submission delays and assessment complications.
Need Support with EU CTIS Submissions?
Contact our regulatory affairs team for guidance on CTIS submission strategy, Directive-to-Regulation transitions, and multi-country trial coordination.